High RIG-I and EFTUD2 expression predicts poor survival in endometrial cancer

Susanne Beyer,Lena Müller,Sophie Mitter,Lucia Keilmann,Sarah Meister,Christina Buschmann,Fabian Kraus,Nicole E. Topalov,Bastian Czogalla,Fabian Trillsch,Alexander Burges,Sven Mahner,Elisa Schmoeckel,Sanja Löb,Stefanie Corradini,Mirjana Kessler,Udo Jeschke,Thomas Kolben
DOI: https://doi.org/10.1007/s00432-022-04271-z
2022-09-08
Journal of Cancer Research and Clinical Oncology
Abstract:Endometrial cancer is the most common gynecological malignancy. The helicase RIG-I, a part of the innate immune system, and EFTUD2, a splicing factor which can upregulate RIG-I expression, are shown to influence tumor growth and disease progression in several malignancies. For endometrial cancer, an immunogenic cancer, data about RIG-I and EFTUD2 are still missing. The aim of this study was to examine the expression of RIG-I and EFTUD2 in endometrial cancer.
oncology
What problem does this paper attempt to address?